First Wave BioPharma Dosed Final Patient In The Phase 2 SPAN Trial Of An Enhanced Enteric Microgranule Delivery Formulation Of Adrulipase For Exocrine Pancreatic Insufficiency In Patients With Cystic Fibrosis; Topline Results Are Anticipated By Mid-2023
Portfolio Pulse from Benzinga Newsdesk
First Wave BioPharma has dosed the final patient in the Phase 2 SPAN trial of Adrulipase for Exocrine Pancreatic Insufficiency in patients with Cystic Fibrosis. The trial uses an enhanced enteric microgranule delivery formulation. Topline results are expected by mid-2023.
June 28, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
First Wave BioPharma's completion of dosing in the Phase 2 trial of Adrulipase could potentially impact the company's stock positively, depending on the results of the trial.
The completion of dosing in the Phase 2 trial is a significant milestone for First Wave BioPharma. However, the impact on the company's stock will largely depend on the results of the trial, which are expected by mid-2023. If the results are positive, it could potentially boost the company's stock.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100